Teladoc Health, Inc. (NYSE:TDOC – Get Rating) has been given a consensus recommendation of “Hold” by the thirty-two ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and six have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $77.70.
TDOC has been the topic of several research analyst reports. Barclays lowered their target price on shares of Teladoc Health from $77.00 to $45.00 in a report on Thursday, April 28th. KeyCorp lowered their target price on shares of Teladoc Health from $180.00 to $100.00 and set an “overweight” rating on the stock in a report on Wednesday, February 23rd. Citigroup downgraded shares of Teladoc Health from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $115.00 to $43.00 in a report on Thursday, April 28th. JPMorgan Chase & Co. downgraded shares of Teladoc Health from an “overweight” rating to a “neutral” rating in a report on Thursday, April 28th. Finally, Evercore ISI lowered their target price on shares of Teladoc Health from $90.00 to $70.00 and set an “inline” rating on the stock in a report on Wednesday, February 23rd.
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
In other Teladoc Health news, SVP Daniel Trencher sold 1,000 shares of the stock in a transaction dated Friday, June 17th. The shares were sold at an average price of $29.12, for a total transaction of $29,120.00. Following the completion of the sale, the senior vice president now directly owns 28,408 shares of the company’s stock, valued at $827,240.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.55% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Oliver Lagore Vanvalin Investment Group purchased a new position in shares of Teladoc Health in the 1st quarter valued at approximately $27,000. American Trust purchased a new position in Teladoc Health during the 1st quarter worth approximately $783,000. Walleye Capital LLC raised its position in Teladoc Health by 121.9% during the 1st quarter. Walleye Capital LLC now owns 15,896 shares of the health services provider’s stock worth $1,147,000 after buying an additional 8,731 shares during the last quarter. Kestra Private Wealth Services LLC purchased a new position in Teladoc Health during the 1st quarter worth approximately $590,000. Finally, Advisory Services Network LLC raised its position in Teladoc Health by 20.8% during the 1st quarter. Advisory Services Network LLC now owns 8,413 shares of the health services provider’s stock worth $607,000 after buying an additional 1,449 shares during the last quarter. 87.17% of the stock is owned by hedge funds and other institutional investors.
TDOC opened at $31.51 on Wednesday. The firm has a market cap of $5.08 billion, a P/E ratio of -0.73 and a beta of 0.81. Teladoc Health has a 1-year low of $27.38 and a 1-year high of $174.32. The company has a 50 day simple moving average of $39.26 and a two-hundred day simple moving average of $63.52. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.94 and a quick ratio of 3.71.
Teladoc Health (NYSE:TDOC – Get Rating) last posted its quarterly earnings results on Wednesday, April 27th. The health services provider reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.08. The business had revenue of $565.35 million during the quarter, compared to analyst estimates of $568.91 million. Teladoc Health had a negative net margin of 321.94% and a negative return on equity of 2.12%. During the same period in the prior year, the business posted $0.13 earnings per share. Equities analysts anticipate that Teladoc Health will post -2.05 earnings per share for the current year.
Teladoc Health Company Profile (Get Rating)
Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Teladoc Health right now?
Before you consider Teladoc Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Teladoc Health wasn’t on the list.
While Teladoc Health currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
